Summary
Elevance Health, Inc. has filed an 8-K report to reaffirm its financial guidance for the full year 2025. The company expects diluted earnings per share to be in the range of $28.30 to $29.00, which includes approximately $5.85 per diluted share in net unfavorable items. Excluding these specific items, the adjusted earnings per diluted share are projected to be between $34.15 and $34.85, consistent with prior statements and not incorporating additional adjustments beyond those reported in Q1 2025. Furthermore, Elevance Health is reiterating its full-year 2025 guidance for the benefit expense ratio, targeting 89.1% with a 50 basis point margin of error. The company also anticipates that 60% of its adjusted shareholders' earnings per diluted share will be realized in the first half of 2025. These reaffirmations reflect management's current assessment of market conditions, operational performance, regulatory environments, and refined business assumptions. Investors are reminded that actual results may differ materially due to inherent uncertainties and risks outlined in the company's SEC filings.
Key Highlights
- 1Reaffirmation of full-year 2025 diluted earnings per share guidance between $28.30 and $29.00.
- 2Inclusion of approximately $5.85 per diluted share in net unfavorable items within the reported EPS guidance.
- 3Projected adjusted shareholders' earnings per diluted share for full year 2025 remain between $34.15 and $34.85.
- 4Reaffirmation of full-year 2025 benefit expense ratio guidance at 89.1% +/- 50 basis points.
- 5Expectation that 60% of adjusted shareholders' earnings per diluted share will be achieved in the first half of 2025.
- 6Guidance reflects current management views on market conditions, operational performance, and regulatory landscape.
- 7Company notes that actual results could materially differ from guidance due to various risks and uncertainties.